The Health Law Firm

AUGUST 21, 2015

By Michael L. Smith, R.R.T., J.D., Board Certified by The Florida Bar in Health Law The US District Court for the Southern District of New York granted a preliminary injunction to Amarin Pharma, Inc. (Amarin), prohibiting the Food and Drug Administration (FDA) from enforcing its off-label marketing ban. The injunction means that Amarin can engage in truthful marketing of Vascepa even when the marketing is used to promote an off-label use of Vascepa.

FDA 40

FDA 40

The Health Law Firm

AUGUST 18, 2015

By George F. Indest III, J.D., M.P.A., LL.M., Board Certified by The Florida Bar in Health Law On July 14, 2015, Ann Maxwell, Assistant Inspector General for Evaluation and Inspections of the Office of Inspector General (OIG), US Department of Health and Human Services (HHS), gave testimony to Congress on the Medicare Part D Program. She presented before the United States House of Representatives Committee on Energy and Commerce and the Subcommittee on Oversight and Investigations.

US Department of Health and Human Services 40

US Department of Health and Human Services Medicare Medicare Fraud 40